

Beaumont

Colleagues,

The current predominant COVID-19 variant, Omicron, is estimated to be responsible for over 90% of our current positive infections. As the virus mutates, the susceptibility to available monoclonal antibodies is shifting. Throughout Beaumont Health, we had opened several clinics for the administration of Regeneron's REGEN-COV (indevimab/casirivimab) and bamlanivimab/etesevimab. Unfortunately, recent data shows that these antibody treatments has limited effectiveness against the Omicron variant. As such, we will be discontinuing the administration of these monoclonal antibodies in both our inpatient settings and outpatient antibody clinics, effective immediately.

The monoclonal antibody, sotrovimab, has been shown to be effective against the Omicron variant. Unfortunately, there is a very limited supply. As we receive distribution from the state, this will become available as we develop the ordering process. On a positive note, we have begun the administration of Evusheld, a long-acting combination of monoclonal antibodies for the prevention of COVID-19 in high-risk individuals. The tier one ordering criteria can be found [here](#). The ordering link is [here](#).

I realize this has been an extremely difficult month for all of our medical and hospital staff. We will continuously keep you updated as these treatment options evolve.

Your support and efforts are greatly appreciated.



Jeffrey S. Fischgrund, M.D.
Chief, Clinical Care Programs
Beaumont Health

This message was sent to all Beaumont physicians, APPs and residents.